EXOME

all the information, none of the junk | biotech • healthcare • life sciences

Former GSK CEO Andrew Witty Named Venture Partner at Hatteras

Xconomy Raleigh-Durham — 

Andrew Witty, former CEO of GlaxoSmithKline (NYSE: GSK), is moving into biotech investing. Hatteras Venture Partners announced that Witty will become a venture partner at the Durham, NC-based firm. His role will include advising Hatteras’ portfolio companies. Witty left GSK earlier this year after serving as CEO for nine years.